Holazo A A, Patel I H, Weinfeld R E, Konikoff J J, Parsonnet M
Eur J Clin Pharmacol. 1986;30(1):109-12. doi: 10.1007/BF00614206.
The steady-state pharmacokinetics and tolerance of ceftriaxone after multiple i.m. doses of 0.5 and 1 g q12 h for 3.5 days were investigated in 12 healthy, adult volunteers. Ceftriaxone was rapidly absorbed after i.m. administration with mean peak times ranging from 1.3 to 1.9 h. Steady-state plasma concentrations were apparent after the third dose of both dosage regimens, with trough plasma concentrations of 24 +/- 6 and 39 +/- 8 micrograms/ml (mean +/- SD) after the 0.5 and 1 g q12 h regimens, respectively. Multiple i.m. administrations of ceftriaxone did not alter its elimination half-life; however, small increases were observed in the plasma clearance and volume of distribution at the 1-g regimen. These increases were attributed to the non-linear binding of ceftriaxone to human plasma proteins, and are therapeutically unimportant. Ceftriaxone was well tolerated and serious or lasting adverse reactions were not encountered in the study.
在12名健康成年志愿者中,研究了每12小时肌肉注射0.5克和1克头孢曲松,连续3.5天的多剂量给药后的稳态药代动力学和耐受性。肌肉注射头孢曲松后吸收迅速,平均达峰时间为1.3至1.9小时。两种给药方案在第三次给药后均出现稳态血药浓度,在每12小时0.5克和1克的给药方案下,谷浓度分别为24±6和39±8微克/毫升(平均值±标准差)。多次肌肉注射头孢曲松未改变其消除半衰期;然而,在1克给药方案下,血浆清除率和分布容积略有增加。这些增加归因于头孢曲松与人血浆蛋白的非线性结合,在治疗上无重要意义。头孢曲松耐受性良好,研究中未出现严重或持续的不良反应。